"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
| Descriptor ID |
D007069
|
| MeSH Number(s) |
D02.455.526.728.650.730.243.250 D02.705.672.500.243.250 D03.383.533.500
|
| Concept/Terms |
Ifosfamide- Ifosfamide
- Isofosfamide
- Isophosphamide
- Iphosphamide
- Iso-Endoxan
- Iso Endoxan
NSC-109,724- NSC-109,724
- NSC 109,724
- NSC109,724
- NSC-109724
- NSC 109724
- NSC109724
|
Below are MeSH descriptors whose meaning is more general than "Ifosfamide".
Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".
This graph shows the total number of publications written about "Ifosfamide" by people in this website by year, and whether "Ifosfamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ifosfamide" by people in Profiles.
-
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1645-1653.
-
Embryonal sarcoma of the liver in pediatric and young adult patients: A report from Children's Oncology Group study ARST0332. Cancer. 2024 Aug 01; 130(15):2683-2693.
-
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13; 403(10435):1460-1471.
-
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma. J Thorac Oncol. 2024 May; 19(5):829-838.
-
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. J Clin Oncol. 2023 11 01; 41(31):4842-4848.
-
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 2023 02 28; 7(4):602-610.
-
Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy. Cancer. 2022 12 01; 128(23):4150-4156.
-
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma. Pediatr Hematol Oncol. 2023 May; 40(4):422-428.
-
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. Cancer Med. 2022 09; 11(18):3471-3478.
-
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma. Cancer Rep (Hoboken). 2022 07; 5(7):e1581.